What Jubilant Pharmova does

Jubilant Pharmova Limited, founded in 1978 and headquartered in Noida, India, is a global pharmaceutical company listed on the NSE (JUBILANTPHARMOVA) and BSE (530019) and part of the Jubilant Bhartia Group. It operates through six business segments — Radiopharma, Allergy Immunotherapy, CDMO Sterile Injectables, CRDMO (Drug Discovery & API), Generics, and Proprietary Novel Drugs — serving global pharmaceutical customers with both contract services and finished-dose products. With FY26 revenue of ₹8,280 crore (approximately $1B), 10,000+ employees, and a growth rate of 14% YoY, it is a vertically integrated player spanning early-stage drug discovery, sterile injectable manufacturing, and commercial product supply.

The company's revenue model blends B2B contract development and manufacturing (CDMO Sterile Injectables and CRDMO) with B2C product sales (Generics, Allergy Immunotherapy, Radiopharma, Proprietary Novel Drugs). The CDMO Sterile Injectables franchise, anchored by the Spokane facility in the US, generated ₹1,755 crore in FY26 (up 38% YoY), with the Spokane site alone contributing ₹1,714 crore (up 48% YoY). Capital intensity is high: $132M has been invested in Spokane Line 3 as of October 2025, with $300M planned by FY28, and recent portfolio actions include the transfer of the API business to Jubilant Biosys in 2026.

Recent strategic activity includes a biologics/ADC partnership with Pierre Fabre (May 2026), tentative USFDA approval for Pantoprazole oral suspension (June 2026), a Spokane USFDA inspection yielding 8 non-sterility observations (June 2026), and the appointment of Daniel J O'Connor as CEO of the Proprietary Novel Drugs division. EBITDA margin narrowed 99 bps to 15.9% in FY26, primarily due to the Montreal facility shutdown, but normalised PAT still grew 7% YoY to ₹442 crore. The combined signals — strong CDMO growth, sustained capex, regulatory progress, and portfolio simplification — describe a company in execution-led expansion mode rather than a defensive turnaround.

Name

Jubilant Pharmova

Legal name

Jubilant Pharmova Limited

Website

https://jubilantpharmova.com

Company type

Public

Founded year

1978

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Jubilant Pharmova is a Noida-headquartered global pharmaceutical company operating across Radiopharma, Allergy Immunotherapy, CDMO Sterile Injectables, CRDMO, Generics, and Proprietary Novel Drugs. With FY26 revenue of ₹8,280 crore, it serves global pharma customers via B2B contract manufacturing and B2C specialty products.

Ownership category

akta.pro rank

Product category

Pharmaceutical Contract Development and Manufacturing (CDMO)

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), In-Vitro Diagnostic Substance Manufacturing (325413)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Sterile Fill-Finish & Aseptic Manufacturing CDMO (HLAGABAH)

akta.pro secondary industries

Radiopharmaceutical CDMO & Manufacturing (GMP Fill-Finish) (HLAIAGAF), Drug Substance–Drug Product Integrated CDMO (HLAGABAG), Generic ANDA/Regulatory Affairs & Submissions (HLAIABAJ), Clinical CROs (Phase I–IV) (HLAGAAAA)

Keywords

• Pharmaceutical contract manufacturing
• Sterile injectable fill-finish
• Radiopharmaceutical products
• Generic drug manufacturing
• Drug discovery services

Headquarters

HQ city

Noida

HQ country

India

HQ region

Asia

Offices12 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Supply Chain, Infrastructure, Marketing or Sales

Revenue model

1. CDMO Sterile Injectables: Contract manufacturing of sterile injectable pharmaceuticals for global pharma companies. Revenue of Rs 1,755 crore in FY26 with 38% growth, driven by incremental revenue from new Line 3 facility in Spokane, US. Growing demand from large US pharma companies seeking domestic manufacturing capacity amid new US tariffs.
2. Generics: Research and development, manufacture, sale and distribution of generic pharmaceuticals globally. Received tentative USFDA approval for Pantoprazole Sodium Delayed Release Oral Suspension, with final approval expected after December 2026 patent expiry.
3. Radiopharma: Development, manufacturing, commercialisation and distribution of radiopharmaceutical products.
4. Allergy Immunotherapy: Manufacturing and distribution of allergenic extracts and standard allergy vaccines. Offering over 200 different allergenic products.
5. Contract Research Development & Manufacturing Organisation (CRDMO): Drug discovery services and Active Pharmaceutical Ingredients (API) manufacturing. Completed transfer of API business to Jubilant Biosys Limited.
6. Proprietary Novel Drugs: Clinical stage biopharmaceutical company developing precision oral medicines with enhanced therapeutic index.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels3 records

Core offering

Jubilant Pharmova is an integrated pharmaceutical company that develops, manufactures and commercializes sterile injectables, radiopharmaceuticals, allergy immunotherapy products, generic drugs, active pharmaceutical ingredients (APIs) and proprietary novel drugs. It operates contract development and manufacturing (CDMO/CRDMO) services for global pharmaceutical companies across facilities in India, the United States and Canada, alongside proprietary product distribution in allergy immunotherapy, generics and radiopharma.

Product overview

Jubilant Pharmova is an integrated global pharmaceuticals company organized into six distinct business segments: Radiopharma (radiopharmaceutical development and manufacturing), Allergy Immunotherapy (allergenic extracts and vaccines), CDMO Sterile Injectables (contract manufacturing of parenteral products), CRDMO (drug discovery and API manufacturing through Jubilant Biosys), Generics (vertically integrated generic pharmaceuticals), and Proprietary Novel Drugs (clinical-stage precision oral medicines). The company operates manufacturing facilities in India (Roorkee, Nanjangud, Noida, Greater Noida), USA (Spokane, Washington), and Canada (Montreal, Quebec), serving global pharmaceutical clients through contract development and manufacturing services.

Differentiator

Problem solved

Functional benefit

Brands

• Jubilant Radiopharma: Development, manufacturing, commercialisation & distribution of radiopharmaceutical products
• Jubilant HollisterStier
• Jubilant Biosys
• Jubilant Generics
• Jubilant Therapeutics
• HSS Allergy

Products and services

• CDMO Sterile Injectables Contract manufacturing of sterile injectable (parenteral) products, ophthalmics, ointments, creams and liquids for global pharmaceutical innovator companies. Operated from Spokane, Washington and Montreal, Canada facilities through Jubilant HollisterStier LLC, with three sterile fill-and-finish lines and a fourth line planned (technology transfer revenues expected by Q4 FY27).
• Radiopharma Development, manufacturing, commercialization and distribution of radiopharmaceutical products for medical diagnostics and therapy, operated through Jubilant DraxImage Limited with manufacturing in Montreal, Canada (Kirkland, Quebec).
• Allergy Immunotherapy Manufacturing and distribution of over 200 different allergenic extracts and standard allergy vaccines for allergy diagnosis and immunotherapy treatment, marketed under the HSS Allergy sub-brand.
• Contract Research Development & Manufacturing Organisation (CRDMO) Integrated drug discovery services and Active Pharmaceutical Ingredient (API) manufacturing operated through Jubilant Biosys Limited, providing end-to-end contract research, development and manufacturing for pharmaceutical partners globally.
• Generics Vertically integrated global generic pharmaceutical business engaged in research and development, manufacture, sale and distribution of generic drugs, operated through Jubilant Generics Limited and Jubilant Cadista Pharmaceuticals Inc. (US market), with manufacturing at the USFDA-approved Solid Dosage facility in Roorkee, Uttarakhand.
• Proprietary Novel Drugs Clinical-stage biopharmaceutical pipeline of precision oral medicines with enhanced therapeutic index, developed and held through Jubilant Therapeutics.

Quantifiable outcome

• Revenue growth of 38% in CDMO Sterile Injectables segment to Rs 1,755 crore
• +2 more outcomes

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• Pierre FabrecoreStrategic or Co-development Partner · 22 May 2026Strategic partnership with Pierre Fabre of France for biologics and antibody-drug conjugates (ADC) development and manufacturing. This partnership strengthens Jubilant Pharmova's CDMO capabilities in the high-growth biologics and ADC segment, complementing its existing sterile injectables business and positioning the company to capture increasing outsourcing demand from global pharma companies.

Scale indicators15 records

Recent moves7 records

Expansion highlights5 records

Broad incumbents

• Lonza Group: Global CDMO leader across biologics, small molecules, and cell & gene therapies. Comparable to Jubilant Pharmova at the integrated CDMO/CRDMO level, particularly with the new Pierre Fabre-driven biologics/ADC capability.
• Aurobindo Pharma: Large Indian generic pharmaceutical manufacturer with USFDA-approved facilities. Comparable to Jubilant Generics business serving the US generic drug market with similar regulatory profile.
• Dr. Reddy's Laboratories: Diversified Indian pharmaceutical company with generics, API, and proprietary products. Broad comparable across Jubilant's generics and proprietary novel drugs segments.

Direct peers

• Catalent: Major US-headquartered CDMO with significant sterile injectable fill-finish capacity. Direct competitor to Jubilant HollisterStier in contract manufacturing of sterile injectables for global pharma.
• Recipharm: European-headquartered CDMO providing sterile fill-finish and injectable manufacturing services. Competes with Jubilant in contract manufacturing for global pharma customers.
• Piramal Pharma Solutions: India-based CDMO offering sterile injectables, API manufacturing, and drug discovery services. Direct competitor across multiple Jubilant business segments including CDMO and CRDMO.
• Syngene International: Indian CRO/CDMO providing drug discovery, development, and manufacturing services. Closely comparable to Jubilant Biosys's CRDMO offering and a key India-based CDMO peer.
• Divi's Laboratories: Indian API and custom synthesis manufacturer. Comparable to Jubilant's API and contract manufacturing business with similar end markets among global generic and innovator pharma.
• Lantheus Holdings: Radiopharmaceutical company focused on diagnostic imaging agents. Direct competitor to Jubilant DraxImage in radiopharma manufacturing and commercialization for diagnostic applications.
• Curium Pharma: Global radiopharmaceutical manufacturer of diagnostic and therapeutic nuclear medicine products. Direct competitor to Jubilant's radiopharma business in the same specialty segment.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/Pharmova
• YouTubeyoutube.com/c/JubilantPharmova
• Facebookfacebook.com/JubilantPharmova
• LinkedInlinkedin.com/company/jubilantpharmova
• Instagraminstagram.com/jubilantpharmova

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Subsidiaries16 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Jubilant Pharmova